Sarah Davis
MPhys
Population Health, School of Medicine and Population Health
Senior Research Fellow
+44 114 222 5209
Full contact details
Population Health, School of Medicine and Population Health
Regent Court (ScHARR)
30 Regent Street
91直播
S1 4DA
- Profile
-
I have over 15 years experience in developing health economic models to evaluate the cost-effectiveness of healthcare interventions including diagnostic tests, risk-assessment tools, and both pharmacological and non-pharmacological treatments. I work primarily on NICE technology appraisals and research projects funded by the NIHR HTA programme. I am a member of ScHARR-TAG and I was the Deputy Director of the NICE Decision Support Unit (DSU) from January 2010 to March 2022
I previously spent three years as the Senior Health Economist at the National Collaborating Centre for Nursing and Supportive Care which developed Clinical Guidelines for NICE. When this centre was merged with three others to form the National Clinical Guideline Centre (NCGC) in April 2009, I joined the NCGC as Health Economics Lead. Prior to this, I was a cost-effectiveness modeller within the HEDS section at ScHARR from 2004 to 2006.
- Research interests
-
My research interests are cost-effectiveness modelling, technology appraisal, and clinical guideline development.
Current projects
- The cost-effectiveness of venous thromboembolism risk assessment tools for hospital inpatients - NIHR127454
- Publications
-
Show: Featured publications All publications
Featured publications
Journal articles
- . British Journal of Haematology, 186(1), 166-168.
- . BMJ, 359.
- . PharmacoEconomics, 35(5), 561-573.
- . Health Technology Assessment, 20(78), 1-406.
- . International Journal of Technology Assessment in Health Care, 30(3), 312-324.
- . Eur J Orthop Surg Traumatol, 24(2), 187-195.
- . Health Qual Life Outcomes, 11, 20.
- . Heart, 99(11), 805-810.
- . Europace, 14(3), 402-409.
- . Eye (Lond), 21(12), 1455-1463.
All publications
Journal articles
- . Value in Health.
- . BMJ Medicine, 3(1), e000408-e000408.
- . Archives of Osteoporosis, 19(1).
- . Journal of Thrombosis and Haemostasis.
- . Research and Practice in Thrombosis and Haemostasis, 7, 101939-101939.
- . JBMR Plus.
- . Age and Ageing, 51(3).
- . Osteoporosis International.
- . Bone, 158.
- . BMJ, 373, n1106.
- . Bone Reports, 14, 100958.
- World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2021): Poster Abstracts. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 32(Suppl 1), 119-410.
- . Health Technology Assessment, 24(46).
- . Health Technology Assessment, 24(29), 1-314.
- . Bone, 130.
- . Health Technology Assessment, 23(63), 1-190.
- . Archives of Osteoporosis, 14(1).
- . Emergency Medicine Journal, 0, 1-6.
- . British Journal of Haematology, 186(1), 166-168.
- . Pharmacoeconomics.
- . BMJ Open, 8(4).
- . PharmacoEconomics, 36(10), 1143-1151.
- . BMJ, 359.
- . PharmacoEconomics, 35(10), 1103-1109.
- . PharmacoEconomics, 35(5), 561-573.
- . Health Technology Assessment, 20(93), 1-154.
- . Health Technology Assessment, 20(78), 1-406.
- . Bone, 89, 52-58.
- . PharmacoEconomics, 33(11), 1187-1194.
- . PharmacoEconomics, 33(3), 225-233.
- . Value in Health, 17(8), 762-771.
- . International Journal of Technology Assessment in Health Care, 30(3), 312-324.
- . Eur J Orthop Surg Traumatol, 24(2), 187-195.
- . Heart, 100(4), 350-350.
- . Trials, 14(1).
- . Pharmacoeconomics, 31(8), 653-661.
- . Health Qual Life Outcomes, 11, 20.
- . Heart.
- . Age Ageing, 42(1), 14-20.
- . Heart, 99(11), 805-810.
- . Health Technol Assess, 16(21), 1-470.
- . Europace, 14(3), 402-409.
- . BRIT MED J, 341.
- . Health Technol Assess, 12(27), iii-124.
- . Eye (Lond), 21(12), 1455-1463.
- Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis.. Health technology assessment (Winchester, England), 11(7).
- . Health Technol Assess, 11(4), 1-134.
- . Health Technol Assess, 11(40), 1-144.
- . Health Technol Assess, 11(7), iii-231.
- . Value Health, 10(1), 32-41.
- . Women's Health Medicine, 3(4), 149-151.
- . Health Technol Assess, 9(22), 1-160.
- . Health Technology Assessment, 1-166.
- . Health Technology Assessment, 1-169.
- . Health and Social Care Delivery Research, 1-275.
- . Osteoporosis International.
- Decision-analysis modelling of effectiveness and cost-effectiveness of pharmacological thromboprophylaxis for surgical inpatients, using variable risk assessment models or other strategies. Journal of Thrombosis and Haemostasis.
- Thromboprophylaxis during pregnancy and the puerperium: a systematic review and economic evaluation to estimate the value of future research. Health Technology Assessment.
- Risk assessment models for venous thromboembolism in pregnancy and in the puerperium: a systematic review. BMJ Open.
- . Health Technology Assessment, 20(78), 407-424.
- . Health Technology Assessment, 19(60), 1-110.
Chapters
Conference proceedings papers
- RESEARCH PRIORITIES REGARDING THE USE OF BISPHOSPHONATES FOR OSTEOPOROSIS: A UK PRIORITY SETTING EXERCISE. RHEUMATOLOGY, Vol. 62
- Thromboprophylaxis during pregnancy and the puerperium: A systematic review, qualitative study and economic evaluation to estimate the value and acceptability of future research. BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, Vol. 130 (pp 20-20)
- Monitoring Bisphosphonate Treatment In Primary Care: PINP And Osteoporosis In 91直播 Evaluation (POSE Study). JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 37 (pp 64-65)
- Addition of symptoms to traditional risk factors improves prediction of those at high risk of vertebral fractures: Results of the Vfrac study. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 37 (pp 60-60)
- ASSESSING THE EFFECTIVENESS OF BISPHOSPHONATES FOR THE PREVENTION OF FRAGILITY FRACTURES: AN UPDATED SYSTEMATIC REVIEW AND NETWORK META-ANALYSES. OSTEOPOROSIS INTERNATIONAL, Vol. 32(SUPPL 1) (pp S270-S270)
- MONITORING BISPHOSPHONATE TREATMENT IN PRIMARY CARE: PINP AND OSTEOPOROSIS IN SHEFFIELD EVALUATION (POSE STUDY). OSTEOPOROSIS INTERNATIONAL, Vol. 32(SUPPL 1) (pp S288-S288)
- . 1.6 General Practice and Primary Care
- . VALUE IN HEALTH, Vol. 16(7) (pp A327-A327)
- Economic evaluation of the use of lanthanum carbonate from an Australian perspective. NEPHROLOGY DIALYSIS TRANSPLANTATION, Vol. 22 (pp 186-186)
- Lanthanum carbonate for the treatment of hyperphosphataemia: Development of a cost effectiveness model. VALUE HEALTH, Vol. 7(6) (pp 805-805)
Reports
Preprints
- Teaching interests
-
My teaching interests include decision modelling in health care and supporting non-health economists to engage with health economic evidence when developing guidance for the NHS.
- Professional activities and memberships
-
Member of NICE Highly Specialised Technologies Evaluation Committee
Links